Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

870 results
MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1965 2
1966 1
1968 2
1969 2
1970 6
1971 2
1972 5
1978 1
1979 2
1980 2
1981 7
1982 7
1983 14
1984 12
1985 29
1986 19
1987 21
1988 26
1989 13
1990 37
1991 16
1992 24
1993 18
1994 29
1995 35
1996 34
1997 30
1998 45
1999 31
2000 28
2001 20
2002 38
2003 22
2004 26
2005 25
2006 31
2007 24
2008 24
2009 20
2010 17
2011 18
2012 20
2013 29
2014 23
2015 20
2016 17
2017 16
2018 15
2019 5
Text availability
Article attribute
Article type
Publication date

Search Results

870 results
Results by year
Filters applied: . Clear all
Page 1
Megestrol acetate for treatment of anorexia-cachexia syndrome.
Ruiz Garcia V, et al. Cochrane Database Syst Rev 2013 - Review. PMID 23543530 Free PMC article.
BACKGROUND: This is an updated version of a previously published review in The Cochrane Library (2005, Issue 2) on 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. Megestrol acetate (MA) is currently used to improve appetite and to increase weight in cancer-associated anorexia. In 1993, MA was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia or unexplained weight loss in patients with AIDS. ...
BACKGROUND: This is an updated version of a previously published review in The Cochrane Library (2005, Issue 2) on 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. Megestrol acetate (MA) is currently used to improve appetite and to increase weight in c …
Megestrol acetate for cachexia-anorexia syndrome. A systematic review.
Ruiz-García V, et al. J Cachexia Sarcopenia Muscle 2018. PMID 29542279 Free PMC article.
In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. ...This is an updated version of a Cochrane systematic review first published in 2005 and later updated in 2013 entitled 'Megestrol acetate for the treatment of anorexia-cachexia syndrome'. ...
In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. ...This is an updated version of a Cochrane systematic review first published in …
Megestrol acetate and mirtazapine for the treatment of unplanned weight loss in the elderly.
Fox CB, et al. Pharmacotherapy 2009 - Review. PMID 19323618
Although several drug interventions have been employed for this problem, megestrol acetate and mirtazapine are becoming increasingly used for appetite stimulation. ...Therefore, the use of megestrol acetate or mirtazapine for weight loss should be thoroughly evaluated on an individual basis. ...
Although several drug interventions have been employed for this problem, megestrol acetate and mirtazapine are becoming increasingly used for appetite stimulation. ...Therefore, the use of megestrol acetate or mirtazapine for weight loss should be thoroughly evaluated on …
Pharmacy Report: Megestrol Acetate-Induced Adrenal Insufficiency.
Nanjappa S, et al. Cancer Control 2016. PMID 27218795
A thorough workup of the case was performed and secondary adrenal insufficiency induced by the administration of megestrol acetate was determined to be the cause. Adrenal insufficiency is a serious disorder that is a potential adverse event of megestrol acetate, a medication used to help patients with cancer cachexia increase their appetite and gain weight. ...
A thorough workup of the case was performed and secondary adrenal insufficiency induced by the administration of megestrol acetate was determined to be the cause. Adrenal insufficiency is a serious disorder that is a potential adverse event of megestrol acetate, a medicat …
Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers.
Kouchaki B, et al. Support Care Cancer 2018 - Clinical Trial. PMID 29442239
We designed this study to test the hypothesis that combination therapy with megestrol acetate (MA) plus celecoxib is superior to MA alone. ...CONCLUSION: Since both MA alone and MA plus celecoxib are associated with improvement of cachexia in GI cancer patients, this study failed to show that adding celecoxib (200 mg/day) to megestrol (320 mg/day) could enhance anti-cachexic effects of megestrol....
We designed this study to test the hypothesis that combination therapy with megestrol acetate (MA) plus celecoxib is superior to MA alone. ...CONCLUSION: Since both MA alone and MA plus celecoxib are associated with improvement of cachexia in GI cancer patients, this study failed to sh …
Megestrol Acetate Induces Declarative Memory Changes and Cortisol Suppression in Healthy Volunteers.
Mason BL, et al. Dement Geriatr Cogn Disord 2018 - Clinical Trial. PMID 30286455
METHODS: Healthy volunteers received each medication combination (placebo and megestrol, phenytoin and megestrol, and placebo and placebo) using a randomized, crossover design. ...CONCLUSION: Changes in memory and cortisol suppression were found in healthy volunteers given megestrol....
METHODS: Healthy volunteers received each medication combination (placebo and megestrol, phenytoin and megestrol, and placebo and placebo) using a randomized, crossover design. ...CONCLUSION: Changes in memory and cortisol suppression were found in healthy volunteers given megestrol
Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
Ha ES, et al. Drug Des Devel Ther 2015. PMID 26345723 Free PMC article.
The extent and rate of dissolution of megestrol acetate increased after the addition of a surfactant into the HPMC solid dispersion nanoparticles. ...These results suggest that the preparation of megestrol acetate solid dispersion nanoparticles using the supercritical antisolvent process is a promising approach to improve the dissolution and absorption properties of megestrol acetate....
The extent and rate of dissolution of megestrol acetate increased after the addition of a surfactant into the HPMC solid dispersion nanoparticles. ...These results suggest that the preparation of megestrol acetate solid dispersion nanoparticles using the supercritical ant …
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.
House L, et al. Xenobiotica 2018. PMID 29050522 Free PMC article.
There is limited knowledge regarding the metabolism of megestrol acetate (MA), as it was approved by FDA in 1971, prior to the availability of modern tools for identifying specific drug-metabolizing enzymes. ...
There is limited knowledge regarding the metabolism of megestrol acetate (MA), as it was approved by FDA in 1971, prior to the availability of modern tools for identifying specific drug-metabolizing enzymes. ...
Clinical Inquiry: Is megestrol acetate safe and effective for malnourished nursing home residents?
Wen FK, et al. J Fam Pract 2018 - Review. PMID 29400904
Megestrol acetate (MA) is neither safe nor effective for stimulating appetite in malnourished nursing home residents. It increases the risk of deep vein thrombosis (strength of recommendation [SOR]: C, 2 retrospective chart reviews), but isn't associated with other new or worsening events or disorders (SOR: B, single randomized controlled trial [RCT]). ...
Megestrol acetate (MA) is neither safe nor effective for stimulating appetite in malnourished nursing home residents. It increases the risk of deep vein thrombosis (strength of recommendation [SOR]: C, 2 retrospective chart reviews), but isn't associated with other new or worsening eve
870 results
Jump to page
Feedback